Mass flow controllers for bioreactors
Alicat now offers mass flow controllers built specifically for professional engineers involved in bioreactor construction and upstream or downstream processes.

The -BIO series units are said to offer the highest reliability in the industry, have a lifetime warranty and resistance to in-line water contamination.
Based on Alicat’s solid state sensor design, these units feature ultra-fast response times as low as 10ms to enable Pharma 4.0; controllable ranges exceeding 2000:1, often eliminating the need for multiple gas lines. Accuracy is said to be as low as .1% of full scale or .5% of reading.
All Alicat -BIO controllers and meters include features tailored to the unique needs of the bioprocessing/biopharmaceutical industry.
- USP Class VI FDA-grade corrosion resistant elastomers are standard to prevent contamination of fragile bioreaction environments.
- 316L stainless steel construction of flow bodies and elements are standard to meet BPE-2016 requirements.
- High-speed EtherCAT or EtherNet/IP interfaces are an option to meet or exceed Pharma 4.0 requirements
- An ultrasharp, modern colour display is present to provide at a glance understanding of process status.
- Every unit has features such as 'gas select' – which allows any unit to be used with CO2, Air, O2, N2 or over 100 other gases with no loss of precision or need for recalibration.
- Units also include 'drive display', allowing new ways to monitor the health of your gas flow process.
- IP66 ingression protection is available as an option, should your operating environment demand it.
Every -BIO is available with a wide range of build options, process connections, protocols and digital interfaces to match almost every bioreactor design. The Bio series is suitable for many types of bioreactors and bioprocess applications; biologics production, biosimilar development, biofuel production, and nuticeutical development.
To learn more, or to get a quotation, simply follow the link: https://www.alicat.com/quote/.
IPE publishes a weekly eNewsletter, delivering a carefully chosen selection of the latest stories straight to your inbox.
Subscribe here

